(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WZZLD89');
window.addEventListener('pushdatalayer', function(event) {
const section = event.detail?.siteSection;
const subsection = event.detail?.siteSubsection;
const pageUrl = event.detail?.pageUrl;
const pageTitle = event.detail?.pageTitle;
const promptSelection = event.detail?.promptSelection;
const formId = event.detail?.formId;
const dataLayerEvent = {
event: event.detail.eventName,
eventCallback: function () {
document.dispatchEvent(new CustomEvent('postdatalayerpush', {
bubbles: true,
composed: true,
detail: event.detail,
}));
},
};
if (section) {
dataLayerEvent['site_section'] = section;
}
if (subsection) {
dataLayerEvent['site_subsection'] = subsection;
}
if (pageUrl) {
dataLayerEvent['pageUrl'] = pageUrl;
}
if (pageTitle) {
dataLayerEvent['pageTitle'] = pageTitle;
}
if(promptSelection){
dataLayerEvent['promptSelection'] = promptSelection;
}
if(formId){
dataLayerEvent['form_ID'] = formId;
}
window.dataLayer = window.dataLayer || [];
window.dataLayer.push(dataLayerEvent);
});
document.addEventListener('checkcookie', () => {
var hasCookie = document.cookie.split(';')
.some((cookie) => cookie.trim().startsWith('CookieConsent='));
document.dispatchEvent(new CustomEvent('hascookie', { detail: hasCookie }));
});
Researchers used artificial intelligence to study medical records from 12,000 people with MS. Their findings suggest that MS is one disease that changes in severity over time, rather than consisting of distinct subtypes. Background: Traditionally, MS has been described as separate subtypes including relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS). These categories have helped guide treatment and research, but they may not fully capture what is happening in the central nervous system at any given time or predict how the disease will progress. Classifying MS based on its underlying biology may be an alternative way to describe the disease and lead to more personalized treatment.The Study: Artificial intelligence (AI) models can quickly scan large amounts of data and find patterns that may not be easily observed by doctors and researchers. In this study, researchers used AI to study medical records from around 12,000 people with MS. The AI looked for unique patterns by analyzing data from clinical visits, brain imaging scans (MRIs), relapse history, and clinical disability tests.Results: The AI model identified 4 features that can be used to describe MS progression. They include physical disability (based on standard tests like the EDSS), brain damage seen on MRI, relapses, and “silent” disease activity (when new brain lesions appear without symptoms).Taking these features into account, authors concluded that MS should be thought of as a spectrum of stages instead of as distinct subtypes. People with MS move along the spectrum over time, and some features, like relapses and silent disease activity, increase the risk of moving to a more advanced stage of disease. Why Does This Matter? This research presents a new way of thinking about MS. Instead of being divided into separate types, MS may instead be one disease that changes over time based on an individual’s underlying biology.This idea is similar to proposals from separate groups of MS experts, including the International Committee on Clinical Trials in MS, who have also suggested rethinking how MS is described. Although official changes to MS descriptions may not happen soon, this perspective could eventually lead to faster diagnosis, earlier treatment, and more personalized care. Learn More… The International Committee on Clinical Trials in MS recently hosted a meeting that focused on the need for updating how MS is described. Read a meeting summary . Listen to a RealTalk MS interview with an MS expert who discusses updating the MS course descriptors.The role of AI in MS research and clinical care is increasing. Read about how doctors and researchers use the tool to improve care and speed discoveries. “AI-driven reclassification of multiple sclerosis progression ” by Habib Ganjgahi, Dieter A. Häring, Piet Aarden, Gordon Graham, Yang Sun, Stephen Gardiner, Wendy Su, Claude Berge, Antje Bischof, Elizabeth Fisher, Laura Gaetano, Stefan P. Thoma, Bernd C. Kieseier, Thomas E. Nichols, Alan J. Thompson, Xavier Montalban, Fred D. Lublin, Ludwig Kappos, Douglas L. Arnold, Robert A. Bermel, Heinz Wiendl and Chris C. Holmes. Published in Nature Medicine (2025). Researchers used artificial intelligence to study medical records from 12,000 people with MS. Their findings suggest that MS is one disease that changes in severity over time, rather than consisting of distinct subtypes. Background: Traditionally, MS has been described as separate subtypes including relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS). These categories have helped guide treatment and research, but they may not fully capture what is happening in the central nervous system at any given time or predict how the disease will progress. Classifying MS based on its underlying biology may be an alternative way to describe the disease and lead to more personalized treatment.The Study: Artificial intelligence (AI) models can quickly scan large amounts of data and find patterns that may not be easily observed by doctors and researchers. In this study, researchers used AI to study medical records from around 12,000 people with MS. The AI looked for unique patterns by analyzing data from clinical visits, brain imaging scans (MRIs), relapse history, and clinical disability tests.Results: The AI model identified 4 features that can be used to describe MS progression. They include physical disability (based on standard tests like the EDSS), brain damage seen on MRI, relapses, and “silent” disease activity (when new brain lesions appear without symptoms).Taking these features into account, authors concluded that MS should be thought of as a spectrum of stages instead of as distinct subtypes. People with MS move along the spectrum over time, and some features, like relapses and silent disease activity, increase the risk of moving to a more advanced stage of disease. Why Does This Matter? This research presents a new way of thinking about MS. Instead of being divided into separate types, MS may instead be one disease that changes over time based on an individual’s underlying biology.This idea is similar to proposals from separate groups of MS experts, including the International Committee on Clinical Trials in MS, who have also suggested rethinking how MS is described. Although official changes to MS descriptions may not happen soon, this perspective could eventually lead to faster diagnosis, earlier treatment, and more personalized care. Learn More… The International Committee on Clinical Trials in MS recently hosted a meeting that focused on the need for updating how MS is described. Read a meeting summary . Listen to a RealTalk MS interview with an MS expert who discusses updating the MS course descriptors.The role of AI in MS research and clinical care is increasing. Read about how doctors and researchers use the tool to improve care and speed discoveries. “AI-driven reclassification of multiple sclerosis progression ” by Habib Ganjgahi, Dieter A. Häring, Piet Aarden, Gordon Graham, Yang Sun, Stephen Gardiner, Wendy Su, Claude Berge, Antje Bischof, Elizabeth Fisher, Laura Gaetano, Stefan P. Thoma, Bernd C. Kieseier, Thomas E. Nichols, Alan J. Thompson, Xavier Montalban, Fred D. Lublin, Ludwig Kappos, Douglas L. Arnold, Robert A. Bermel, Heinz Wiendl and Chris C. Holmes. Published in Nature Medicine (2025). About Multiple Sclerosis Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS. About the National Multiple Sclerosis Society The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalmssociety.org , Facebook , X (formerly known as Twitter), Instagram , YouTube or 1-800-344-4867 . About Multiple Sclerosis Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS. About the National Multiple Sclerosis Society The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalmssociety.org , Facebook , X (formerly known as Twitter), Instagram , YouTube or 1-800-344-4867 .
AI MS Course Descriptors